Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted equity awards on April 1, 2022 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The inducement awards consist of options to purchase an aggregate of 32,500 shares of Astria's common stock and were granted as an inducement material to the new employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.48, which is equal to the closing price of Astria's common stock on April 1, 2022 (the "Grant Date"). Each option will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employment start date of each employee (which, in each case, preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.


These press releases may also interest you

at 14:47
As the nationwide nursing shortage persists, the Health Foundation of South Florida, the region's largest philanthropic organization focused on achieving health equity in underserved communities, announced a $1 million investment to fund expanded...

at 14:45
PharmAla Biotech (the 'Company') has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP MDMA at scale. The company believes that it is currently the only source for commercially-available GMP MDMA...

at 14:40
Over the past decade, countless dedicated athletes, fitness lovers, and everyone in between have made Thermovextm by EVOchem Nutrition® a necessary and favorite staple in their everyday routine. This metabolic/thermogenic powerhouse has even garnered...

at 14:35
Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released...

at 14:34
Xenocor, a Utah-based medical device company, today announced newly issued U.S. patent protection for the Saberscope system from the United States Patent and Trademark Office (USPTO). The Saberscope system is the world's first true HD, fog free,...

at 14:30
According to Coherent Market Insights, the global remote patient monitoring devices market is estimated to be valued at US$ 1,192.5 million in 2022 and is expected to exhibit a CAGR of 7.4 % during the forecast period (2022-2030). Key Trends and...



News published on 4 april 2022 at 08:05 and distributed by: